In the setting of thoracic neoplasms, it has been described that SMARCA4 loss correlates with poorer outcome and expression of SOX2, CD34, and SALL4, and SMARCB1 loss is mainly seen in thoracic neoplasms of a mesenchymal lineage [31]. This evidence concerns the gene SMARCB1 and neoplasm of thorax.